

Davine Hofste op Bruinink

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3015857/publications.pdf>

Version: 2024-02-01

15
papers

250
citations

1163117

8
h-index

1199594

12
g-index

15
all docs

15
docs citations

15
times ranked

392
citing authors

#	ARTICLE	IF	CITATIONS
1	The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. <i>Nature Immunology</i> , 2021, 22, 769-780.	14.5	107
2	Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial. <i>Blood Cancer Journal</i> , 2021, 11, 106.	6.2	31
3	IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. <i>Endocrine</i> , 2019, 64, 673-684.	2.3	23
4	Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. <i>Leukemia</i> , 2022, 36, 1887-1897.	7.2	23
5	Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 1364-1373.	4.1	22
6	Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients: Results from the EMN02/HO95 phase 3 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8011-8011.	1.6	15
7	Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile. <i>Journal of Clinical Oncology</i> , 2022, 40, 3132-3150.	1.6	13
8	Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network. <i>Haematologica</i> , 2021, 106, 1496-1499.	3.5	9
9	Differential Effect of Upfront Intensification Treatment in Genetically Defined Myeloma Risk Groups - a Combined Analysis of ISS, Del17p and SKY92 Scores in the EMN-02/HOVON-95 MM Trial. <i>Blood</i> , 2018, 132, 3186-3186.	1.4	3
10	Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis. <i>Blood</i> , 2016, 128, 3271-3271.	1.4	2
11	Flowcytometric Minimal Residual Disease Assessment in the EMN-02/HOVON-95 MM Trial: Used Methods and a Comparison of Their Sensitivity. <i>Blood</i> , 2016, 128, 2072-2072.	1.4	1
12	Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission " results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial. <i>BMC Cancer</i> , 2022, 22, 147.	2.6	1
13	Targeted Genomic Mutation Panel (M3 P) Results from 504 Multiple Myeloma (MM) Patients. <i>Blood</i> , 2015, 126, 1795-1795.	1.4	0
14	M3P Sequencing Panel Identifies TP53 Mutational Status As a Prognostic Factor in Chemotherapy-Naive Multiple Myeloma. <i>Blood</i> , 2015, 126, 2984-2984.	1.4	0
15	Whole-Exome and mRNA Sequencing of Multiple Myeloma Reveal Transformation to a More High-Risk and Proliferative Tumor at Relapse. <i>Blood</i> , 2018, 132, 3157-3157.	1.4	0